Table 2.
Characteristics of all patients.
| Variable | Hb Range | Group Effect P Value | Time Effect | ||||||
|---|---|---|---|---|---|---|---|---|---|
| <8.5 g/dl (n=249) | 8.5–9.99 g/dl (n=697) | 10.0–11.49 g/dl (n=1272) | 11.5–12.99 g/dl (n=1067) | 13–14.49 g/dl (n=359) | >14.5 g/dl (n=87) | Unit Change | Estimated P Value | ||
| Age (yr) | 9.9±5.4 | 9.2±4.9 | 9.8±4.6 | 10.1±4.4 | 10.1±5.1 | 10.6±5.4 | 0.18 | – | – |
| Pubertal male (%) | 11.2 | 10.3 | 16.4 | 19.2 | 18.7 | 19.5 | 0.02 | 0.114 | 0.19 |
| PD vintage (yr) | 1.7±1.6 | 1.8±1.6 | 1.7.±1.3 | 1.7±1.3 | 1.6±1.5 | 1.3±1.7 | 0.03 | – | – |
| Use of biocompatible PD fluids (%) | 22.1 | 26.8 | 31.8 | 35.3 | 30.9 | 35.6 | 0.42 | −0.120 | 0.11 |
| PET 4h-D/Pcreatinine | 0.68±0.16 (n=61) | 0.68±0.14 (n=158) | 0.66±0.12 (n=247) | 0.64±0.13 (n=244) | 0.61±0.16 (n=70) | 0.63±0.13 (n=22) | 0.59 | −0.0032 | 0.55 |
| Estimated deviation from dry weight (%) | 2.02±3.71 | 2.09±2.90 | 1.41±2.46 | 1.32±2.04 | 1.49±3.29 | 1.51±2.35 | <0.001 | −0.0502 | 0.43 |
| PD fluid turnover (L/m2 per day) | 6.33±2.75 | 6.65±2.55 | 6.98±2.60 | 6.76±2.53 | 6.85±2.91 | 6.44±2.63 | 0.07 | 0.587 | <0.001 |
| Ultrafiltration volume (L/m2 per day) | 0.65±0.41 | 0.56±0.35 | 0.55±0.37 | 0.50±0.32 | 0.57±0.41 | 0.53±0.45 | 0.008 | 0.0353 | <0.001 |
| Urine volume (L/m2 per day) | 0.40±0.52 | 0.55±0.57 | 0.61±0.53 | 0.71±0.59 | 0.67±0.66 | 0.73±0.68 | 0.003 | −0.088 | <0.001 |
| Total fluid output (L/m2 per day) | 1.07±0.55 (n=225) | 1.13±0.55 (n=599) | 1.18±0.54 (n=1097) | 1.23±0.53 (n=939) | 1.26±0.64 (n=300) | 1.27±0.68 (n=68) | 0.20 | 0.0423 | <0.001 |
| ESA use (%) | |||||||||
| None | 4.8 | 4.2 | 3.9 | 7.7 | 16.4 | 31.0 | <0.001 | −0.212 | 0.03 |
| Epoetin | 79.5 | 80.2 | 77.3 | 73.5 | 71.9 | 57.5 | 0.003 | −0.154 | 0.02 |
| Darbepoetin | 14.9 | 14.6 | 17.3 | 17.2 | 10.6 | 11.5 | 0.21 | 0.225 | 0.004 |
| ESA dose (1000 U/m2 per week) | 7.12±4.53 (n=191) | 6.12±3.22 (n=545) | 5.26±3.12 (n=1002) | 4.89±3.25 (n=769) | 4.19±3.13 (n=240) | 5.83±4.81 (n=52) | <0.001 | 0.0036 | 0.96 |
| Iron use (%) | |||||||||
| None | 18.1 | 20.1 | 17.4 | 17.2 | 15.3 | 23.0 | 0.44 | 0.288 | <0.001 |
| Oral | 60.6 | 67.0 | 65.3 | 68.6 | 66.3 | 70.1 | 0.20 | −0.361 | <0.001 |
| Intravenous (with or without oral) | 21.3 | 12.9 | 17.3 | 14.2 | 18.4 | 6.9 | 0.07 | 0.0808 | 0.29 |
| Biochemistry | |||||||||
| Hemoglobin (g/dl) | 7.6±0.6 | 9.3±0.3 | 10.7±0.3 | 12.1±0.3 | 13.5±0.4 | 15.2±0.7 | 0.02 | 0.0223 | <0.001 |
| Serum ferritin (ng/ml) | 262 (125–486) (n=130) | 234 (121–402) (n=429) | 188 (85–356) (n=768) | 160 (75–312) (n=625) | 164 (66–336) (n=211) | 128 (59–304) (n=56) | 0.04 | 15.3 | <0.001 |
| Serum albumin (g/l) | 33.1±6.6 | 35.4±5.1 | 36.3±4.9 | 37.2±4.7 | 38.6±4.9 | 39.1±4.9 | <0.001 | 0.0884 | 0.34 |
| Plasma PTH (pg/ml) | 452 (177–740) | 325 (122–675) | 218 (99–494) | 213 (104–436) | 215 (95–465) | 197 (79–412) | <0.001 | 15.6 | 0.06 |
| Cardiovascular variables | |||||||||
| Systolic BP SDS | 1.34±1.63 | 1.12±1.39 | 0.92±1.20 | 0.87±1.13 | 0.72±1.36 | 0.66±1.56 | <0.001 | −0.109 | <0.001 |
| Diastolic BP SDS | 1.19±1.27 | 1.03±1.25 | 0.90±1.07 | 0.85±1.03 | 0.74±1.23 | 0.74±1.44 | 0.002 | −0.153 | <0.001 |
| Hypertensive (%) | 49.8 | 43.5 | 36.9 | 36.4 | 32.1 | 42.7 | 0.002 | −0.146 | 0.005 |
| LV mass index | 66.8±49.4 (n=80) | 48.9±22.5 (n=263) | 48.4±27.5 (n=489) | 48.6±33.1 (n=414) | 44.2±26.1 (n=134) | 53.1±30.2 (n=32) | <0.001 | −2.45 | 0.01 |
| LV hypertrophy (%) | 62.5 | 43.0 | 41.5 | 39.4 | 37.3 | 43.8 | 0.05 | −0.135 | 0.08 |
Data are given as mean ± SD, median (IQR), or percentage as appropriate. Group effect column denotes differences between Hb group means. Time effect column shows the unit change per observation year. Numbers in parentheses denote available observations. PET 4h-D/Pcreatinine, peritoneal equilibration test 4 hour dialysate plasma to creatinine ratio; SDS, standard deviation score; LV, left ventricular.